Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

AbbVie Announces Approval of SKYRIZI™ for the Treatment of Psoriasis in US, Canada and Japan

AbbVie, a research-based global biopharmaceutical company, announced on March 26, 2019 that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI™, an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies. This approval marked the first country approval in the world for SKYRIZI.

On April 18, 2019, the approval of  SKYRIZI in Japan was followed by Health Canada's approval of SKYRIZI for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Later, on April 23, 2019, the U.S. Food and Drug Administration (FDA) approved SKYRIZI, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy shortly after.

Most recently, on April 30, 2019, the European Commission Approves SKYRIZI for the Treatment of Moderate to Severe Plaque Psoriasis.

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). While the exact cause of plaque psoriasis is unknown, the body may produce too much of a protein called IL-23. IL-23 is one of several proteins that may contribute to excess inflammation inside the body, which can lead to painful, red, itchy, or burning plaques on the skin. SKYRIZI is an immune protein similar to those produced by the body. It works by binding to the excess IL-23. This can help reduce the overproduction of IL-23 in your immune system.

Read more about the FDA approval of  SKYRIZI™ for the treatment of psoriasis in the U.S.:
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis >

Read more about Health Canada's approval of SKYRIZI™ for the treatment of psoriasis in Canada:
Health Canada Approves SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis >

Read more about the approval of SKYRIZI™ in Europe:
European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis >

Read more about the Japanese Ministry of Health, Labour and Welfare's approval of SKYRIZI™  for the treatment of psoriasis in Japan:
AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan >


UPCOMING EVENT

Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas

Monday, june 10, 2019
1:30 – 4:30 pm
milan, italy
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

This website uses cookies. Please ensure your cookies are enabled. 
OK